NewsRoom Articles - Page 141 of 207

ThursdayAug 05, 2021 1:23 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters…

ThursdayAug 05, 2021 12:14 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Marks Milestone Moment as First Psychedelic Biotech to Trade on NYSE American Exchange

Company announces official approval for its common shares to be listed, traded on NYSE American Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader Companies that list on NYSE American can leverage a wide range of advantages In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading…

ThursdayAug 05, 2021 12:05 pm

Brain Scientific Inc.’s (BRSF) Rapid Response EEG Devices Provide Cost-Effective Solution for Neurology Market

Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026 Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market. Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive…

WednesdayAug 04, 2021 2:15 pm

AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening

Summary After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. According to US marketing research firm Frost-Sullivan, AnPac Bio ranked top three globally in terms of clinical and commercial test sample numbers in the space of new cancer detection technologies in 2019. In the next five years, AnPac Bio strives to become a global leader…

WednesdayAug 04, 2021 11:32 am

How Depression Impacts Men, Women Differently

Researchers have reported that women and men can experience depression differently, and while both genders may share many common symptoms and signs, understanding these differences may better help those who suffer from this condition. The Connors Center for Women’s Health and Gender Biology director of research Jill Goldstein states that understanding the sex differences when it comes to depression is essential because it helps understand the condition better. Goldstein notes that among the most significant differences between the genders when it comes to depression is the fact that women are twice as likely to develop the condition in comparison with…

WednesdayAug 04, 2021 11:09 am

RYAH Group Inc. (CSE: RYAH) Supporting U.S. Changes in Cannabis Research

New cultivators have approved for federally funded studies in the U.S., and 575 DEA-licensed researchers are standing by, ready for the change RYAH's ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research RYAH continues to expand its global clinical and distribution network for plant-based medicine and digital patient care The U.S. is putting an end to its 50-year long prohibition on Cannabis Research (https://ibn.fm/YIrkv). New cultivators have now been approved for federally funded studies. With over 575 DEA-licensed researchers across the U.S., the future of cannabis…

TuesdayAug 03, 2021 2:48 pm

New Evidence Links Fibromyalgia to Immune System

A team of researchers from the Karolinska Institutet in Stockholm, the University of Liverpool and King’s College London has found that many symptoms of fibromyalgia occur when the antibodies in an individual increase the activity of pain-sensing nerves. Fibromyalgia is a chronic syndrome that causes mental distress and bodily pain. The disease is classified as a rheumatic condition because it causes myofascial pain or soft tissue pain. Individuals living with fibromyalgia also have sensitivity to cold and pressure all over their bodies, in addition to experiencing emotional distress, fatigue and trouble sleeping. It is estimated that roughly 4 million adults…

TuesdayAug 03, 2021 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Is ‘One to Watch’

InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica InMed retains all commercial rights to its IntegraSyn manufacturing system InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to…

MondayAug 02, 2021 12:26 pm

Study Finds Extensive Variations in Cost, Transparency of Thyroid Cancer Care

A mandate from the Centers for Medicare and Medicaid Services directed that from Jan. 1, 2021, all hospitals in the United States provide pricing information online about their services and items. The objective of this mandate is to help inform patients about the cost of procedures and services before they receive them. Researchers from Brigham and Women’s Hospital and Massachusetts Eye and Ear used this data to examine price variation and transparency for thyroid cancer treatment. They discovered that both price and transparency differed greatly, with the costs of various services having huge variations and only one-half of the cancer…

MondayAug 02, 2021 9:30 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection The global cancer diagnostics market is expected to reach $249.6 billion by 2026 AnPac Bio-Medical Science…